Please assess the completion status of the following clinical trial:

Trial Title: Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 18 to 60 years on the day of inclusion~* Provision of a signed Informed Consent Form~* Able to attend all scheduled visits and comply with all trial procedures~* For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence for at least 4 weeks prior to each vaccination, until at least 4 weeks after each vaccination)~* Entitlement to national social security~Exclusion Criteria :~* For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test~* Breast-feeding woman~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances~* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator~* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures~* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination~* Planned receipt of any vaccine in the 4 weeks following any trial vaccination~* Known human immunodeficiency virus (HIV), Hepatitis B surface (HBs) antigen, or Hepatitis C seropositivity~* Previous vaccination against rabies with any vaccine (in pre- or post-exposure regimen)~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) vaccination~* Subject at high risk for rabies exposure during the trial period~* Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent~* Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.~* Study site employee who is involved in the protocol and may have direct access to trial related data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- VRVg Group (Type: EXPERIMENTAL): None
- Verorab Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).